Robert Clarke

List of Publications by Year in Descending Order

338 papers	19,300 citations	61 h-index	132 g-index
380 ext. papers	21,237 ext. citations	6 avg, IF	6.15 L-index

#	Paper	IF	Citations
338	Comparative assessment and novel strategy on methods for imputing proteomics data.. *Scientific Reports*, **2022**, 12, 1067	4.9	2
337	ChIP-BIT2: a software tool to detect weak binding events using a Bayesian integration approach. *BMC Bioinformatics*, **2021**, 22, 193	3.6	
336	Inhibition of Antiestrogen-Promoted Pro-Survival Autophagy and Tamoxifen Resistance in Breast Cancer through Vitamin D Receptor. *Nutrients*, **2021**, 13,	6.7	3
335	ChIP-GSM: Inferring active transcription factor modules to predict functional regulatory elements. *PLoS Computational Biology*, **2021**, 17, e1009203	5	0
334	IntAPT: integrated assembly of phenotype-specific transcripts from multiple RNA-seq profiles. *Bioinformatics*, **2021**, 37, 650-658	7.2	0
333	Experimental models of endocrine responsive breast cancer: strengths, limitations, and use. *Cancer Drug Resistance (Alhambra, Calif)*, **2021**, 4, 762-783	4.5	2
332	Data-driven detection of subtype-specific differentially expressed genes. *Scientific Reports*, **2021**, 11, 332	4.9	1
331	Identifying intracellular signaling modules and exploring pathways associated with breast cancer recurrence. *Scientific Reports*, **2021**, 11, 385	4.9	1
330	BICORN: An R package for integrative inference of de novo cis-regulatory modules. *Scientific Reports*, **2020**, 10, 7960	4.9	1
329	RNA interference screening methods to identify proliferation determinants and mechanisms of resistance to immune attack. *Methods in Enzymology*, **2020**, 636, 299-322	1.7	1
328	Maternal obesity increases offspring B mammary cancer recurrence and impairs tumor immune response. *Endocrine-Related Cancer*, **2020**, 27, 469-482	5.7	5
327	Biomedical image characterization and radiogenomics **2020**, 585-613		0
326	IB kinase-E mediated phosphorylation triggers IRF-1 degradation in breast cancer cells. *Neoplasia*, **2020**, 22, 459-469	6.4	1
325	A systems biology approach to discovering pathway signaling dysregulation in metastasis. *Cancer and Metastasis Reviews*, **2020**, 39, 903-918	9.6	3
324	Radiogenomic signatures reveal multiscale intratumour heterogeneity associated with biological functions and survival in breast cancer. *Nature Communications*, **2020**, 11, 4861	17.4	18
323	debCAM: a bioconductor R package for fully unsupervised deconvolution of complex tissues. *Bioinformatics*, **2020**, 36, 3927-3929	7.2	5
322	Poly-ADP-Ribosylation of Estrogen Receptor-Alpha by PARP1 Mediates Antiestrogen Resistance in Human Breast Cancer Cells. *Cancers*, **2019**, 11,	6.6	5

321	Role of Protein Translation in Unfolded Protein Response. *Cancer Drug Discovery and Development*, **2019**, 109-120	0.3	
320	Glutamine Metabolism Drives Growth in Advanced Hormone Receptor Positive Breast Cancer. *Frontiers in Oncology*, **2019**, 9, 686	5.3	21
319	Systems biology: perspectives on multiscale modeling in research on endocrine-related cancers. *Endocrine-Related Cancer*, **2019**, 26, R345-R368	5.7	9
318	Introduction: The Unfolded Protein Response. *Cancer Drug Discovery and Development*, **2019**, 1-15	0.3	
317	Roles of Spliced and Unspliced XBP1 in Breast Cancer. *Cancer Drug Discovery and Development*, **2019**, 121-132	0.3	
316	The Unfolded Protein Response as an Integrator of Response to Endocrine Therapy in Estrogen Receptor Positive Breast Cancer. *Cancer Drug Discovery and Development*, **2019**, 163-180	0.3	
315	Effects of Jaeumkanghwa-tang on tamoxifen responsiveness in preclinical ER+ breast cancer model. *Endocrine-Related Cancer*, **2019**, 26, 339-353	5.7	1
314	Estrogen-Induced Apoptosis in Breast Cancers Is Phenocopied by Blocking Dephosphorylation of Eukaryotic Initiation Factor 2 Alpha (eIF2)Protein. *Molecular Cancer Research*, **2019**, 17, 918-928	6.6	11
313	CRNET: an efficient sampling approach to infer functional regulatory networks by integrating large-scale ChIP-seq and time-course RNA-seq data. *Bioinformatics*, **2018**, 34, 1733-1740	7.2	8
312	SparseIso: a novel Bayesian approach to identify alternatively spliced isoforms from RNA-seq data. *Bioinformatics*, **2018**, 34, 56-63	7.2	6
311	Autophagy and unfolded protein response (UPR) regulate mammary gland involution by restraining apoptosis-driven irreversible changes. *Cell Death Discovery*, **2018**, 4, 40	6.9	17
310	Dielectrophoretic properties distinguish responses to estrogen and fulvestrant in breast cancer cells. *Sensors and Actuators B: Chemical*, **2018**, 277, 186-194	8.5	2
309	Lifetime Genistein Intake Increases the Response of Mammary Tumors to Tamoxifen in Rats. *Clinical Cancer Research*, **2017**, 23, 814-824	12.9	35
308	Breast cancer cell obatoclax response characterization using passivated-electrode insulator-based dielectrophoresis. *Electrophoresis*, **2017**, 38, 1988-1995	3.6	21
307	Introduction: Cancer Gene Networks. *Methods in Molecular Biology*, **2017**, 1513, 1-9	1.4	2
306	DM-BLD: differential methylation detection using a hierarchical Bayesian model exploiting local dependency. *Bioinformatics*, **2017**, 33, 161-168	7.2	16
305	Effects of In Utero Exposure to Ethinyl Estradiol on Tamoxifen Resistance and Breast Cancer Recurrence in a Preclinical Model. *Journal of the National Cancer Institute*, **2017**, 109,	9.7	18
304	PSSV: a novel pattern-based probabilistic approach for somatic structural variation identification. *Bioinformatics*, **2017**, 33, 177-183	7.2	2

303 EGR1 regulates cellular metabolism and survival in endocrine resistant breast cancer. *Oncotarget*, **2017**, 8, 96865-96884   3.3   23

302 Autophagy, Inflammation, and Breast Cancer Risk **2017**, 359-372

301 CyNetSVM: A Cytoscape App for Cancer Biomarker Identification Using Network Constrained Support Vector Machines. *PLoS ONE*, **2017**, 12, e0170482   3.7   3

300 Linking autophagy with inflammation through IRF1 signaling in ER+ breast cancer. *Molecular and Cellular Oncology*, **2016**, 3, e1023928   1.2   3

299 Acquisition of estrogen independence induces TOB1-related mechanisms supporting breast cancer cell proliferation. *Oncogene*, **2016**, 35, 1643-56   9.2   22

298 Biologically inspired survival analysis based on integrating gene expression as mediator with genomic variants. *Computers in Biology and Medicine*, **2016**, 77, 231-9   7   1

297 G-DOC Plus - an integrative bioinformatics platform for precision medicine. *BMC Bioinformatics*, **2016**, 17, 193   3.6   29

296 Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). *Autophagy*, **2016**, 12, 1-222   10.2   3838

295 ChIP-BIT: Bayesian inference of target genes using a novel joint probabilistic model of ChIP-seq profiles. *Nucleic Acids Research*, **2016**, 44, e65   20.1   6

294 Associations of Epicardial, Abdominal, and Overall Adiposity With Atrial Fibrillation. *Circulation: Arrhythmia and Electrophysiology*, **2016**, 9,   6.4   75

293 Mathematical modelling of transcriptional heterogeneity identifies novel markers and subpopulations in complex tissues. *Scientific Reports*, **2016**, 6, 18909   4.9   39

292 Social isolation induces autophagy in the mouse mammary gland: link to increased mammary cancer risk. *Endocrine-Related Cancer*, **2016**, 23, 839-56   5.7   12

291 Endoplasmic Reticulum Stress Protein GRP78 Modulates Lipid Metabolism to Control Drug Sensitivity and Antitumor Immunity in Breast Cancer. *Cancer Research*, **2016**, 76, 5657-5670   10.1   74

290 Inhibition of BET proteins impairs estrogen-mediated growth and transcription in breast cancers by pausing RNA polymerase advancement. *Breast Cancer Research and Treatment*, **2015**, 150, 265-78   4.4   29

289 Recommendations concerning the new U.S. National Institutes of Health initiative to balance the sex of cells and animals in preclinical research. *FASEB Journal*, **2015**, 29, 1646-52   0.9   50

288 Molecular mechanisms of tamoxifen-associated endometrial cancer (Review). *Oncology Letters*, **2015**, 9, 1495-1501   2.6   81

287 The Changing Spectrum of Biomedical and Clinical Research **2015**, 137-148

286 Endocrine resistance in breast cancer--An overview and update. *Molecular and Cellular Endocrinology*, **2015**, 418 Pt 3, 220-34   4.4   200

285	TMEM33: a new stress-inducible endoplasmic reticulum transmembrane protein and modulator of the unfolded protein response signaling. *Breast Cancer Research and Treatment*, **2015**, 153, 285-97	4.4	15
284	Role of GRP78 in promoting therapeutic-resistant breast cancer. *Future Medicinal Chemistry*, **2015**, 7, 1529-34	4.1	29
283	UNDO: a Bioconductor R package for unsupervised deconvolution of mixed gene expressions in tumor samples. *Bioinformatics*, **2015**, 31, 137-9	7.2	42
282	ER decreases breast cancer cell survival by regulating the IRE1/XBP-1 pathway. *Oncogene*, **2015**, 34, 4130-41	9.2	38
281	NF-B signaling is required for XBP1 (unspliced and spliced)-mediated effects on antiestrogen responsiveness and cell fate decisions in breast cancer. *Molecular and Cellular Biology*, **2015**, 35, 379-90	4.8	54
280	KDDN: an open-source Cytoscape app for constructing differential dependency networks with significant rewiring. *Bioinformatics*, **2015**, 31, 287-9	7.2	16
279	Autophagy inhibitor 3-methyladenine potentiates apoptosis induced by dietary tocotrienols in breast cancer cells. *European Journal of Nutrition*, **2015**, 54, 265-72	5.2	35
278	Dynamic Modeling of the Interaction Between Autophagy and Apoptosis in Mammalian Cells. *CPT: Pharmacometrics and Systems Pharmacology*, **2015**, 4, 263-72	4.5	53
277	BACOM2.0 facilitates absolute normalization and quantification of somatic copy number alterations in heterogeneous tumor. *Scientific Reports*, **2015**, 5, 13955	4.9	5
276	S88 The viral mimic polyinosinic: polycytidylic acid (Poly I:C) induces TRPA1 channel hyper-responsiveness in an adult human stem cell-derived sensory neuronal model. *Thorax*, **2015**, 70, A50.2-A51	7.3	1
275	BMRF-MI: integrative identification of protein interaction network by modeling the gene dependency. *BMC Genomics*, **2015**, 16 Suppl 7, S10	4.5	3
274	Overcoming cancer resistance. *Future Medicinal Chemistry*, **2015**, 7, 1471	4.1	
273	Blockage of Lysosomal Degradation Is Detrimental to Cancer Cell Survival: Role of Autophagy Activation **2015**, 121-133		2
272	Application of metabolomics in drug resistant breast cancer research. *Metabolites*, **2015**, 5, 100-18	5.6	38
271	Unfolding the Role of Stress Response Signaling in Endocrine Resistant Breast Cancers. *Frontiers in Oncology*, **2015**, 5, 140	5.3	24
270	BMRF-Net: a software tool for identification of protein interaction subnetworks by a bagging Markov random field-based method. *Bioinformatics*, **2015**, 31, 2412-4	7.2	10
269	Comparison of tamoxifen and letrozole response in mammary preneoplasia of ER and aromatase overexpressing mice defines an immune-associated gene signature linked to tamoxifen resistance. *Carcinogenesis*, **2015**, 36, 122-32	4.6	13
268	Interferon regulatory factor-1 signaling regulates the switch between autophagy and apoptosis to determine breast cancer cell fate. *Cancer Research*, **2015**, 75, 1046-55	10.1	27

267	A new class of small molecule estrogen receptor-alpha antagonists that overcome anti-estrogen resistance. *Oncotarget*, **2015**, 6, 40388-404	3.3	2
266	Integrating Proteotoxic Stress Response Pathways for Induction of Cell Death in Cancer Cells: Molecular Mechanisms and Therapeutic Opportunities **2015**, 183-202		
265	Hydroxychloroquine inhibits autophagy to potentiate antiestrogen responsiveness in ER+ breast cancer. *Clinical Cancer Research*, **2014**, 20, 3222-32	12.9	136
264	Knowledge-fused differential dependency network models for detecting significant rewiring in biological networks. *BMC Systems Biology*, **2014**, 8, 87	3.5	23
263	Mitochondria directly donate their membrane to form autophagosomes during a novel mechanism of parkin-associated mitophagy. *Cell and Bioscience*, **2014**, 4, 16	9.8	45
262	Inhibiting glucose-regulated protein 78 modulates lipid metabolism through controlling stearoyl-CoA desaturase 1. *Cancer & Metabolism*, **2014**, 2,	5.4	78
261	Glutamine metabolism and the unfolded protein response in MYC-driven breast cancer. *Cancer & Metabolism*, **2014**, 2,	5.4	78
260	Enhancing reproducibility in cancer drug screening: how do we move forward?. *Cancer Research*, **2014**, 74, 4016-23	10.1	64
259	Knockdown of estrogen receptor-☐induces autophagy and inhibits antiestrogen-mediated unfolded protein response activation, promoting ROS-induced breast cancer cell death. *FASEB Journal*, **2014**, 28, 3891-905	0.9	67
258	Mathematical models of the transitions between endocrine therapy responsive and resistant states in breast cancer. *Journal of the Royal Society Interface*, **2014**, 11, 20140206	4.1	23
257	Blockage of Lysosomal Degradation is Detrimental to Cancer Cell Survival **2014**, 269-281		
256	Integrative Analysis Workflow for Untargeted Metabolomics in Translational Research. *Metabolomics: Open Access*, **2014**, 04,		1
255	Aromatase inhibitor plus ovarian suppression as adjuvant therapy in premenopausal women with breast cancer. *Cancer Biology and Therapy*, **2014**, 15, 1586-7	4.6	13
254	BSSV: Bayesian based somatic structural variation identification with whole genome DNA-seq data. *Annual International Conference of the IEEE Engineering in Medicine and Biology Society IEEE Engineering in Medicine and Biology Society Annual International Conference*, **2014**, 2014, 3937-40	0.9	1
253	BADGE: a novel Bayesian model for accurate abundance quantification and differential analysis of RNA-Seq data. *BMC Bioinformatics*, **2014**, 15 Suppl 9, S6	3.6	7
252	Small-molecule "BRCA1-mimetics" are antagonists of estrogen receptor-☐*Molecular Endocrinology*, **2014**, 28, 1971-86		4
251	AISAIC: a software suite for accurate identification of significant aberrations in cancers. *Bioinformatics*, **2014**, 30, 431-3	7.2	8
250	Integration of Network Biology and Imaging to Study Cancer Phenotypes and Responses. *IEEE/ACM Transactions on Computational Biology and Bioinformatics*, **2014**, 11, 1009-19	3	11

#	Reference	IF	Cit
249	Robust identification of transcriptional regulatory networks using a Gibbs sampler on outlier sum statistic. *Bioinformatics*, **2014**, 30, 2242-2242	7.2	78
248	MYC regulates the unfolded protein response and glucose and glutamine uptake in endocrine resistant breast cancer. *Molecular Cancer*, **2014**, 13, 239	42.1	58
247	When is a vesicle not just a vesicle: mitochondrial spheroids and mitochondrial autophagosomes. *Cell and Bioscience*, **2014**, 4, 66	9.8	6
246	VAV3 mediates resistance to breast cancer endocrine therapy. *Breast Cancer Research*, **2014**, 16, R53	8.3	21
245	Soluble-E-cadherin activates HER and IAP family members in HER2+ and TNBC human breast cancers. *Molecular Carcinogenesis*, **2014**, 53, 893-906	5	24
244	Unsupervised deconvolution of dynamic imaging reveals intratumor vascular heterogeneity and repopulation dynamics. *PLoS ONE*, **2014**, 9, e112143	3.7	9
243	Do conditionally reprogrammed cell cultures represent the tumors they have been isolated from with high fidelity?. *Journal of Clinical Oncology*, **2014**, 32, e22140-e22140	2.2	
242	Estrogen receptor-β signaling and localization regulates autophagy and unfolded protein response activation in ER+ breast cancer. *Receptors & Clinical Investigation*, **2014**, 1,		8
241	Monoclonal antibody against the ectodomain of E-cadherin (DECMA-1) suppresses breast carcinogenesis: involvement of the HER/PI3K/Akt/mTOR and IAP pathways. *Clinical Cancer Research*, **2013**, 19, 3234-46	12.9	30
240	mAPC-GibbsOS: an integrated approach for robust identification of gene regulatory networks. *BMC Systems Biology*, **2013**, 7 Suppl 5, S4	3.5	3
239	Reconstruction of transcriptional regulatory networks by stability-based network component analysis. *IEEE/ACM Transactions on Computational Biology and Bioinformatics*, **2013**, 10, 1347-58	3	7
238	Modelling the effect of GRP78 on anti-oestrogen sensitivity and resistance in breast cancer. *Interface Focus*, **2013**, 3, 20130012	3.9	24
237	Modeling the estrogen receptor to growth factor receptor signaling switch in human breast cancer cells. *FEBS Letters*, **2013**, 587, 3327-34	3.8	20
236	Identifying early events of gene expression in breast cancer with systems biology phylogenetics. *Cytogenetic and Genome Research*, **2013**, 139, 206-14	1.9	11
235	Targeting GRP78 and antiestrogen resistance in breast cancer. *Future Medicinal Chemistry*, **2013**, 5, 1047-57		21
234	Module-based breast cancer classification. *International Journal of Data Mining and Bioinformatics*, **2013**, 7, 284-302	0.5	13
233	Reconstructing transcriptional regulatory networks by probabilistic network component analysis **2013**,		1
232	Advancing Translational Research through Facility Design in Non-AMC Hospitals. *Herd*, **2013**, 6, 126-37	2.4	2

231	Identifying protein interaction subnetworks by a bagging Markov random field-based method. *Nucleic Acids Research*, **2013**, 41, e42	20.1	30
230	GX15-070 (obatoclax) induces apoptosis and inhibits cathepsin D- and L-mediated autophagosomal lysis in antiestrogen-resistant breast cancer cells. *Molecular Cancer Therapeutics*, **2013**, 12, 448-59	6.1	47
229	In silico discovery of mitosis regulation networks associated with early distant metastases in estrogen receptor positive breast cancers. *Cancer Informatics*, **2013**, 12, 31-51	2.4	13
228	A novel statistical approach to identify co-regulatory gene modules **2013**,		2
227	Genomic and network analysis to study the origin of ovarian cancer. *Systems Biomedicine (Austin, Tex)*, **2013**, 1, 55-64		1
226	Regulatory component analysis: a semi-blind extraction approach to infer gene regulatory networks with imperfect biological knowledge. *Signal Processing*, **2012**, 92, 1902-1915	4.4	4
225	Gamma-tocotrienol induced apoptosis is associated with unfolded protein response in human breast cancer cells. *Journal of Nutritional Biochemistry*, **2012**, 23, 93-100	6.3	50
224	Vitamin E succinate inhibits survivin and induces apoptosis in pancreatic cancer cells. *Genes and Nutrition*, **2012**, 7, 83-9	4.3	14
223	Glucose-regulated protein 78 controls cross-talk between apoptosis and autophagy to determine antiestrogen responsiveness. *Cancer Research*, **2012**, 72, 3337-49	10.1	123
222	Antiestrogen Resistance and the Application of Systems Biology. *Drug Discovery Today Disease Mechanisms*, **2012**, 9, e11-e17		2
221	Genome-wide identification of significant aberrations in cancer genome. *BMC Genomics*, **2012**, 13, 342	4.5	27
220	Heat shock 70 kDa protein 5/glucose-regulated protein 78 "AMP"ing up autophagy. *Autophagy*, **2012**, 8, 1827-9	10.2	21
219	Guidelines for the use and interpretation of assays for monitoring autophagy. *Autophagy*, **2012**, 8, 445-544	10.2	2783
218	Influence of berry polyphenols on receptor signaling and cell-death pathways: implications for breast cancer prevention. *Journal of Agricultural and Food Chemistry*, **2012**, 60, 5693-708	5.7	93
217	Robust identification of transcriptional regulatory networks using a Gibbs sampler on outlier sum statistic. *Bioinformatics*, **2012**, 28, 1990-7	7.2	8
216	Endoplasmic reticulum stress, the unfolded protein response, autophagy, and the integrated regulation of breast cancer cell fate. *Cancer Research*, **2012**, 72, 1321-31	10.1	153
215	Tyrosine-phosphorylated caveolin-1 (Tyr-14) increases sensitivity to paclitaxel by inhibiting BCL2 and BCLxL proteins via c-Jun N-terminal kinase (JNK). *Journal of Biological Chemistry*, **2012**, 287, 17682-17692	5.4	45
214	Effect of Berry Extracts and Bioactive Compounds on Fulvestrant (ICI 182,780) Sensitive and Resistant Cell Lines. *International Journal of Breast Cancer*, **2012**, 2012, 147828	2.3	5

#	Reference	IF	Cit
213	Interaction of dietary polyphenols with molecular signaling pathways of antiestrogen resistance: possible role in breast cancer recurrence. *Hormone Molecular Biology and Clinical Investigation*, **2012**, 9, 127-41	1.3	8
212	Reconstruction of Transcription Regulatory Networks by Stability-Based Network Component Analysis. *Lecture Notes in Computer Science*, **2012**, 36-47	0.9	
211	G-DOC: a systems medicine platform for personalized oncology. *Neoplasia*, **2011**, 13, 771-83	6.4	42
210	G-CODE: enabling systems medicine through innovative informatics **2011**, 12, P38		4
209	Cannibalism, cell survival, and endocrine resistance in breast cancer. *Breast Cancer Research*, **2011**, 13, 311	8.3	6
208	Dynamic modelling of oestrogen signalling and cell fate in breast cancer cells. *Nature Reviews Cancer*, **2011**, 11, 523-32	31.3	154
207	Autophagy and endocrine resistance in breast cancer. *Expert Review of Anticancer Therapy*, **2011**, 11, 1283-94	3.5	113
206	Identifying cancer biomarkers by network-constrained support vector machines. *BMC Systems Biology*, **2011**, 5, 161	3.5	61
205	Motif-guided sparse decomposition of gene expression data for regulatory module identification. *BMC Bioinformatics*, **2011**, 12, 82	3.6	13
204	NTP-CERHR expert panel report on the developmental toxicity of soy infant formula. *Birth Defects Research Part B: Developmental and Reproductive Toxicology*, **2011**, 92, 421-68		69
203	DDN: a caBIG analytical tool for differential network analysis. *Bioinformatics*, **2011**, 27, 1036-8	7.2	33
202	GIST: a Gibbs sampler to identify intracellular signal transduction pathways. *Annual International Conference of the IEEE Engineering in Medicine and Biology Society IEEE Engineering in Medicine and Biology Society Annual International Conference*, **2011**, 2011, 2434-7	0.9	1
201	Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer. *Endocrine-Related Cancer*, **2011**, 18, 333-45	5.7	202
200	Overexpression of the dominant-negative form of interferon regulatory factor 1 in oligodendrocytes protects against experimental autoimmune encephalomyelitis. *Journal of Neuroscience*, **2011**, 31, 8329-41	6.6	21
199	Endoplasmic reticulum stress, the unfolded protein response, and gene network modeling in antiestrogen resistant breast cancer. *Hormone Molecular Biology and Clinical Investigation*, **2011**, 5, 35-44	1.3	39
198	The Role of Interferon Regulatory Factor-1 (IRF1) in Overcoming Antiestrogen Resistance in the Treatment of Breast Cancer. *International Journal of Breast Cancer*, **2011**, 2011, 912102	2.3	31
197	PUGSVM: a caBIG analytical tool for multiclass gene selection and predictive classification. *Bioinformatics*, **2011**, 27, 736-8	7.2	15
196	IFNgamma restores breast cancer sensitivity to fulvestrant by regulating STAT1, IFN regulatory factor 1, NF-kappaB, BCL2 family members, and signaling to caspase-dependent apoptosis. *Molecular Cancer Therapeutics*, **2010**, 9, 1274-85	6.1	62

195	Changes in mammary caveolin-1 signaling pathways are associated with breast cancer risk in rats exposed to estradiol in utero or during prepuberty. *Hormone Molecular Biology and Clinical Investigation*, **2010**, 2, 227-234	1.3	3
194	Multilevel support vector regression analysis to identify condition-specific regulatory networks. *Bioinformatics*, **2010**, 26, 1416-22	7.2	18
193	Module-Based Biomarker Discovery in Breast Cancer **2010**,		1
192	The proapoptotic molecule BLID interacts with Bcl-XL and its downregulation in breast cancer correlates with poor disease-free and overall survival. *Clinical Cancer Research*, **2010**, 16, 2939-48	12.9	15
191	Orphan nuclear receptors in breast cancer pathogenesis and therapeutic response. *Endocrine-Related Cancer*, **2010**, 17, R213-31	5.7	35
190	DBC-1 mediates endocrine resistant breast cancer cell survival. *Cell Cycle*, **2010**, 9, 1218-9	4.7	13
189	Differential Dependency Network Analysis to Identify Topological Changes in Biological Networks **2010**, 185-203		
188	BCL2 and CASP8 regulation by NF-kappaB differentially affect mitochondrial function and cell fate in antiestrogen-sensitive and -resistant breast cancer cells. *FASEB Journal*, **2010**, 24, 2040-55	0.9	71
187	Frequent loss of heterozygosity at the interferon regulatory factor-1 gene locus in breast cancer. *Breast Cancer Research and Treatment*, **2010**, 121, 227-31	4.4	27
186	Knowledge-guided gene ranking by coordinative component analysis. *BMC Bioinformatics*, **2010**, 11, 162	3.6	6
185	Co-inhibition of BCL-W and BCL2 restores antiestrogen sensitivity through BECN1 and promotes an autophagy-associated necrosis. *PLoS ONE*, **2010**, 5, e8604	3.7	56
184	Reconstruction of gene regulatory modules in cancer cell cycle by multi-source data integration. *PLoS ONE*, **2010**, 5, e10268	3.7	9
183	Cross phenotype normalization of microarray data. *Frontiers in Bioscience - Elite*, **2010**, 2, 171-86	1.6	1
182	Signaling Pathways in the Normal and Neoplastic Breast **2010**, 2699-2706		
181	Differential dependency network analysis to identify condition-specific topological changes in biological networks. *Bioinformatics*, **2009**, 25, 526-32	7.2	97
180	Reverse engineering module networks by PSO-RNN hybrid modeling. *BMC Genomics*, **2009**, 10 Suppl 1, S15	4.5	28
179	Gene network signaling in hormone responsiveness modifies apoptosis and autophagy in breast cancer cells. *Journal of Steroid Biochemistry and Molecular Biology*, **2009**, 114, 8-20	5.1	63
178	The role of preclinical animal models in breast cancer drug development. *Breast Cancer Research*, **2009**, 11 Suppl 3, S22	8.3	16

177	Identification of condition-specific regulatory modules through multi-level motif and mRNA expression analysis. *International Journal of Computational Biology and Drug Design*, **2009**, 2, 1-20	0.4	
176	Biomarker identification by knowledge-driven multilevel ICA and motif analysis. *International Journal of Data Mining and Bioinformatics*, **2009**, 3, 365-81	0.5	8
175	The role of X-box binding protein-1 in tumorigenicity. *Drug News and Perspectives*, **2009**, 22, 241-6		59
174	Approaches to working in high-dimensional data spaces: gene expression microarrays. *British Journal of Cancer*, **2008**, 98, 1023-8	8.7	45
173	The properties of high-dimensional data spaces: implications for exploring gene and protein expression data. *Nature Reviews Cancer*, **2008**, 8, 37-49	31.3	370
172	Network motif-based identification of transcription factor-target gene relationships by integrating multi-source biological data. *BMC Bioinformatics*, **2008**, 9, 203	3.6	30
171	caBIG VISDA: modeling, visualization, and discovery for cluster analysis of genomic data. *BMC Bioinformatics*, **2008**, 9, 383	3.6	11
170	Knowledge-guided multi-scale independent component analysis for biomarker identification. *BMC Bioinformatics*, **2008**, 9, 416	3.6	20
169	Motif-directed network component analysis for regulatory network inference. *BMC Bioinformatics*, **2008**, 9 Suppl 1, S21	3.6	17
168	Network motif-based identification of breast cancer susceptibility genes. *Annual International Conference of the IEEE Engineering in Medicine and Biology Society IEEE Engineering in Medicine and Biology Society Annual International Conference*, **2008**, 2008, 5696-9	0.9	22
167	Gene signaling pathways mediating the opposite effects of prepubertal low-fat and high-fat n-3 polyunsaturated fatty acid diets on mammary cancer risk. *Cancer Prevention Research*, **2008**, 1, 532-45	3.2	21
166	ERRgamma mediates tamoxifen resistance in novel models of invasive lobular breast cancer. *Cancer Research*, **2008**, 68, 8908-17	10.1	76
165	Using Laser Tweezers For Manipulating Isolated Neurons In Vitro. *Journal of Visualized Experiments*, **2008**,	1.6	2
164	Integrative Network Component Analysis for Regulatory Network Reconstruction **2008**, 196-207		
163	Sparse Decomposition of Gene Expression Data to Infer Transcriptional Modules Guided by Motif Information **2008**, 244-255		
162	Annotating breast cancer microarray samples using ontologies **2008**, 414-8	0.7	
161	Gene module identification from microarray data using nonnegative independent component analysis. *Gene Regulation and Systems Biology*, **2008**, 1, 349-63	2	9
160	Classification algorithms for phenotype prediction in genomics and proteomics. *Frontiers in Bioscience - Landmark*, **2008**, 13, 691-708	2.8	40

159 A ground truth based comparative study on clustering of gene expression data. *Frontiers in Bioscience - Landmark*, **2008**, 13, 3839-49 | 2.8 | 5

158 Human Tumours in Animal Hosts **2007**, | | 1

157 The A4396G polymorphism in interferon regulatory factor 1 is frequently expressed in breast cancer cell lines. *Cancer Genetics and Cytogenetics*, **2007**, 175, 61-4 | | 15

156 Caveolin-1 tyrosine phosphorylation enhances paclitaxel-mediated cytotoxicity. *Journal of Biological Chemistry*, **2007**, 282, 5934-43 | 5.4 | 54

155 Progressive loss of estrogen receptor alpha cofactor recruitment in endocrine resistance. *Molecular Endocrinology*, **2007**, 21, 2615-26 | | 19

154 VISDA: an open-source caBIG analytical tool for data clustering and beyond. *Bioinformatics*, **2007**, 23, 2024-7 | 7.2 | 15

153 Gene selection for multiclass prediction by weighted Fisher criterion. *Eurasip Journal on Bioinformatics and Systems Biology*, **2007**, 64628 | | 8

152 Human X-box binding protein-1 confers both estrogen independence and antiestrogen resistance in breast cancer cell lines. *FASEB Journal*, **2007**, 21, 4013-27 | 0.9 | 149

151 Gene Module Identification from Microarray Data Using Nonnegative Independent Component Analysis. *Gene Regulation and Systems Biology*, **2007**, 1, 117762500700100 | 2 | 4

150 Disruption of estrogen receptor DNA-binding domain and related intramolecular communication restores tamoxifen sensitivity in resistant breast cancer. *Cancer Cell*, **2006**, 10, 487-99 | 24.3 | 61

149 AIB1 gene amplification and the instability of polyQ encoding sequence in breast cancer cell lines. *BMC Cancer*, **2006**, 6, 111 | 4.8 | 10

148 Inferring network interactions using recurrent neural networks and swarm intelligence. *Annual International Conference of the IEEE Engineering in Medicine and Biology Society*, **2006**, 2006, 4241-4 | | 4

147 Optimized multilayer perceptrons for molecular classification and diagnosis using genomic data. *Bioinformatics*, **2006**, 22, 755-61 | 7.2 | 23

146 Physical and functional interactions between Cas and c-Src induce tamoxifen resistance of breast cancer cells through pathways involving epidermal growth factor receptor and signal transducer and activator of transcription 5b. *Cancer Research*, **2006**, 66, 7007-15 | 10.1 | 80

145 Endocrine therapy resistance can be associated with high estrogen receptor alpha (ERalpha) expression and reduced ERalpha phosphorylation in breast cancer models. *Endocrine-Related Cancer*, **2006**, 13, 1121-33 | 5.7 | 42

144 Meta-analysis of soy intake and breast cancer risk. *Journal of the National Cancer Institute*, **2006**, 98, 459-71 | | 365

143 Inference of Gene Regulatory Networks from Time Course Gene Expression Data Using Neural Networks and Swarm Intelligence **2006**, | | 9

142 Estrogen receptor alpha positive breast tumors and breast cancer cell lines share similarities in their transcriptome data structures **2006**, 29, 1581 | | 6

141	Latent variable and nICA modeling of pathway gene module composite. *Annual International Conference of the IEEE Engineering in Medicine and Biology Society*, **2006**, 2006, 5872-5		4
140	Expression patterns among interferon regulatory factor-1, human X-box binding protein-1, nuclear factor kappa B, nucleophosmin, estrogen receptor-alpha and progesterone receptor proteins in breast cancer tissue microarrays **2006**, 28, 67		4
139	Expression patterns among interferon regulatory factor-1, human X-box binding protein-1, nuclear factor kappa B, nucleophosmin, estrogen receptor-alpha and progesterone receptor proteins in breast cancer tissue microarrays. *International Journal of Oncology*, **2006**, 28, 67-76	1	22
138	Estrogen receptor alpha positive breast tumors and breast cancer cell lines share similarities in their transcriptome data structures. *International Journal of Oncology*, **2006**, 29, 1581-9	1	21
137	Interferon regulatory factor-1 (IRF-1) exhibits tumor suppressor activities in breast cancer associated with caspase activation and induction of apoptosis. *Carcinogenesis*, **2005**, 26, 1527-35	4.6	104
136	Antiestrogens, aromatase inhibitors, and apoptosis in breast cancer. *Vitamins and Hormones*, **2005**, 71, 201-37	2.5	65
135	Multidrug resistance/P-glycoprotein and breast cancer: review and meta-analysis. *Seminars in Oncology*, **2005**, 32, S9-15	5.5	112
134	Mechanisms mediating the effects of prepubertal (n-3) polyunsaturated fatty acid diet on breast cancer risk in rats. *Journal of Nutrition*, **2005**, 135, 2946S-2952S	4.1	34
133	The p160 family coactivators regulate breast cancer cell proliferation and invasion through autocrine/paracrine activity of SDF-1alpha/CXCL12. *Carcinogenesis*, **2005**, 26, 1706-15	4.6	57
132	The nuclear factor kappa B inhibitor parthenolide restores ICI 182,780 (Faslodex; fulvestrant)-induced apoptosis in antiestrogen-resistant breast cancer cells. *Molecular Cancer Therapeutics*, **2005**, 4, 33-41	6.1	58
131	Robust feature selection by weighted Fisher criterion for multiclass prediction in gene expression profiling **2004**,		2
130	Expression of an estrogen receptor variant lacking exon 3 in derivatives of MCF-7 cells with acquired estrogen independence or tamoxifen resistance. *Journal of Molecular Endocrinology*, **2004**, 32, 935-45	4.5	8
129	interferon regulatory factor-1 mediates the proapoptotic but not cell cycle arrest effects of the steroidal antiestrogen ICI 182,780 (faslodex, fulvestrant). *Cancer Research*, **2004**, 64, 4030-9	10.1	56
128	Evaluation of gene expression profile of keratinocytes in response to JP-8 jet fuel. *Toxicology and Applied Pharmacology*, **2004**, 200, 93-102	4.6	7
127	Gene selection in class space for molecular classification of cancer. *Science in China Series F: Information Sciences*, **2004**, 47, 301		2
126	Common origins of MDA-MB-435 cells from various sources with those shown to have melanoma properties. *Clinical and Experimental Metastasis*, **2004**, 21, 543-52	4.7	68
125	LCC15-MB cells are MDA-MB-435: a review of misidentified breast and prostate cell lines. *Clinical and Experimental Metastasis*, **2004**, 21, 535-41	4.7	14
124	Discriminatory Mining of Gene Expression Microarray Data. *Journal of Signal Processing Systems*, **2003**, 35, 255-272		13

123	Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling. *Oncogene*, **2003**, 22, 7316-39	9.2	370
122	Cadmium mimics the in vivo effects of estrogen in the uterus and mammary gland. *Nature Medicine*, **2003**, 9, 1081-4	50.5	428
121	ATP binding cassette transporters and drug resistance in breast cancer. *Endocrine-Related Cancer*, **2003**, 10, 43-73	5.7	187
120	Estrogen withdrawal-induced NF-kappaB activity and bcl-3 expression in breast cancer cells: roles in growth and hormone independence. *Molecular and Cellular Biology*, **2003**, 23, 6887-900	4.8	95
119	Iterative normalization of cDNA microarray data. *IEEE Transactions on Information Technology in Biomedicine*, **2002**, 6, 29-37		31
118	Functionally active estrogen receptor isoform profiles in the breast tumors of African American women are different from the profiles in breast tumors of Caucasian women. *Cancer*, **2002**, 94, 615-23	6.4	44
117	Block principal component analysis with application to gene microarray data classification. *Statistics in Medicine*, **2002**, 21, 3465-74	2.3	28
116	C-7 analogues of progesterone as potent inhibitors of the P-glycoprotein efflux pump. *Journal of Medicinal Chemistry*, **2002**, 45, 390-8	8.3	26
115	Do estrogens always increase breast cancer risk?. *Journal of Steroid Biochemistry and Molecular Biology*, **2002**, 80, 163-74	5.1	48
114	Animal models of endocrine-responsive and -unresponsive breast cancers **2002**, 191-208		
113	Control of Proliferation in the Normal and Neoplastic Breast **2002**, 73-91		
112	Development and validation of a method for using breast core needle biopsies for gene expression microarray analyses. *Clinical Cancer Research*, **2002**, 8, 1155-66	12.9	70
111	Association of interferon regulatory factor-1, nucleophosmin, nuclear factor-kappaB, and cyclic AMP response element binding with acquired resistance to Faslodex (ICI 182,780). *Cancer Research*, **2002**, 62, 3428-37	10.1	70
110	Dietary modulation of pregnancy estrogen levels and breast cancer risk among female rat offspring. *Clinical Cancer Research*, **2002**, 8, 3601-10	12.9	65
109	The enantioselective binding of mefloquine enantiomers to P-glycoprotein determined using an immobilized P-glycoprotein liquid chromatographic stationary phase. *Pharmaceutical Research*, **2001**, 18, 1327-30	4.5	11
108	Competitive and allosteric interactions in ligand binding to P-glycoprotein as observed on an immobilized P-glycoprotein liquid chromatographic stationary phase. *Molecular Pharmacology*, **2001**, 59, 62-8	4.3	30
107	Constitutive expression of the steroid sulfatase gene supports the growth of MCF-7 human breast cancer cells in vitro and in vivo. *Endocrinology*, **2001**, 142, 1497-505	4.8	33
106	Molecular and pharmacological aspects of antiestrogen resistance. *Journal of Steroid Biochemistry and Molecular Biology*, **2001**, 76, 71-84	5.1	113

105	Where do selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs) now fit into breast cancer treatment algorithms?. *Journal of Steroid Biochemistry and Molecular Biology*, **2001**, 79, 227-37	5.1	25
104	Maternal and prepubertal diet, mammary development and breast cancer risk. *Journal of Nutrition*, **2001**, 131, 154S-157S	4.1	46
103	Constitutive Expression of the Steroid Sulfatase Gene Supports the Growth of MCF-7 Human Breast Cancer Cells in Vitroand in Vivo **2001**,		15
102	Cellular and molecular pharmacology of antiestrogen action and resistance. *Pharmacological Reviews*, **2001**, 53, 25-71	22.5	245
101	Breast cancer: dietary and environmental oestrogens. *Biologist*, **2001**, 48, 21-6		4
100	Development of an immobilized P-glycoprotein stationary phase for on-line liquid chromatographic determination of drug-binding affinities. *Biomedical Applications*, **2000**, 739, 33-7		32
99	Introduction and overview: sex steroids in the mammary gland. *Journal of Mammary Gland Biology and Neoplasia*, **2000**, 5, 245-50	2.4	12
98	Identification of twenty alternatively spliced estrogen receptor alpha mRNAs in breast cancer cell lines and tumors using splice targeted primer approach. *Journal of Steroid Biochemistry and Molecular Biology*, **2000**, 72, 249-58	5.1	63
97	Reversal of tamoxifen resistance of human breast carcinomas in vivo by neutralizing antibodies to transforming growth factor-beta. *Journal of the National Cancer Institute*, **1999**, 91, 46-53	9.7	58
96	Use of ERE and reporter gene constructs to assess putative estrogenic activity. *Journal of Medicinal Food*, **1999**, 2, 143-9	2.8	
95	Prepubertal exposure to zearalenone or genistein reduces mammary tumorigenesis. *British Journal of Cancer*, **1999**, 80, 1682-8	8.7	155
94	LCC15-MB: a vimentin-positive human breast cancer cell line from a femoral bone metastasis. *Clinical and Experimental Metastasis*, **1999**, 17, 193-204	4.7	8
93	Growth and phenotypic characterization of porcine coronary artery smooth muscle cells. *In Vitro Cellular and Developmental Biology - Animal*, **1999**, 35, 136-43	2.6	5
92	The influence of maternal diet on breast cancer risk among female offspring. *Nutrition*, **1999**, 15, 392-401	4.8	59
91	Inhibition of P-glycoprotein activity and reversal of multidrug resistance in vitro by rosemary extract. *European Journal of Cancer*, **1999**, 35, 1541-5	7.5	73
90	Differential distribution of protein phosphatase 2A in human breast carcinoma cell lines and its relation to estrogen receptor status. *Cancer Letters*, **1999**, 136, 143-51	9.9	19
89	Inhibition of estrogen receptor function promotes porcine coronary artery smooth muscle cell proliferation. *Steroids*, **1999**, 64, 472-80	2.8	11
88	ER in normal and pre-cancerous breast. *Breast Cancer Research*, **1999**, 1, 1	8.3	

87	Stromelysin-1 promotes mammary carcinogenesis. *Breast Cancer Research*, **1999**, 1, 1	8.3	
86	Organochlorine pesticides: an effect on estrogen activity?. *Breast Cancer Research*, **1999**, 2, 1	8.3	
85	Progesterone in mouse mammary gland carcinogenesis. *Breast Cancer Research*, **1999**, 2, 1	8.3	
84	Maternal exposure to genistein during pregnancy increases carcinogen-induced mammary tumorigenesis in female rat offspring. *Oncology Reports*, **1999**, 6, 1089-95	3.5	120
83	The Estrogenicity of Selected Nutrients, Phytochemicals, Pesticides, and Pollutants **1999**, 537-567		
82	Timing of dietary fat exposure and mammary tumorigenesis: Role of estrogen receptor and protein kinase C activity **1998**, 188, 5-12		9
81	Two-dimensional gel electrophoresis analyses identify nucleophosmin as an estrogen regulated protein associated with acquired estrogen-independence in human breast cancer cells. *Journal of Steroid Biochemistry and Molecular Biology*, **1998**, 67, 391-402	5.1	58
80	The LCC15-MB human breast cancer cell line expresses osteopontin and exhibits an invasive and metastatic phenotype. *Experimental Cell Research*, **1998**, 241, 273-84	4.2	43
79	Maternal genistein exposure mimics the effects of estrogen on mammary gland development in female mouse offspring. *Oncology Reports*, **1998**, 5, 609-16	3.5	61
78	Timing of dietary fat exposure and mammary tumorigenesis: Role of estrogen receptor and protein kinase C activity **1998**, 5-12		
77	Timing of dietary fat exposure and mammary tumorigenesis: role of estrogen receptor and protein kinase C activity. *Molecular and Cellular Biochemistry*, **1998**, 188, 5-12	4.2	2
76	Autoantibodies to the nuclear phosphoprotein nucleophosmin in breast cancer patients. *Cancer Epidemiology Biomarkers and Prevention*, **1998**, 7, 1109-15	4	15
75	Multidrug resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significance. *Journal of the National Cancer Institute*, **1997**, 89, 917-31	9.7	357
74	Steroid metabolism in the hormone dependent MCF-7 human breast carcinoma cell line and its two hormone resistant subpopulations MCF-7/LCC1 and MCF-7/LCC2. *Journal of Steroid Biochemistry and Molecular Biology*, **1997**, 63, 275-81	5.1	11
73	A maternal diet high in n - 6 polyunsaturated fats alters mammary gland development, puberty onset, and breast cancer risk among female rat offspring. *Proceedings of the National Academy of Sciences of the United States of America*, **1997**, 94, 9372-7	11.5	223
72	Animal models of breast cancer: experimental design and their use in nutrition and psychosocial research. *Breast Cancer Research and Treatment*, **1997**, 46, 117-33	4.4	19
71	Issues in experimental design and endpoint analysis in the study of experimental cytotoxic agents in vivo in breast cancer and other models. *Breast Cancer Research and Treatment*, **1997**, 46, 255-78	4.4	46
70	Induction of apoptosis by tamoxifen and ICI 182780 in primary breast cancer. *International Journal of Cancer*, **1997**, 72, 608-13	7.5	82

69	MCF7/LCC9: an antiestrogen-resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182,780 confers an early cross-resistance to the nonsteroidal antiestrogen tamoxifen. *Cancer Research*, **1997**, 57, 3486-93	10.1	131
68	Breast cancer risk in rats fed a diet high in n-6 polyunsaturated fatty acids during pregnancy. *Journal of the National Cancer Institute*, **1996**, 88, 1821-7	9.7	70
67	Acquired estrogen independence and antiestrogen resistance in breast cancer: estrogen receptor driven phenotypes?. *Trends in Endocrinology and Metabolism*, **1996**, 7, 291-301	8.8	27
66	Specific binding of estradiol to rat coronary artery smooth muscle cells. *Journal of Steroid Biochemistry and Molecular Biology*, **1996**, 58, 83-8	5.1	14
65	Animal models of breast cancer: their diversity and role in biomedical research. *Breast Cancer Research and Treatment*, **1996**, 39, 1-6	4.4	52
64	Human breast cancer cell line xenografts as models of breast cancer. The immunobiologies of recipient mice and the characteristics of several tumorigenic cell lines. *Breast Cancer Research and Treatment*, **1996**, 39, 69-86	4.4	104
63	MDA435/LCC6 and MDA435/LCC6MDR1: ascites models of human breast cancer. *British Journal of Cancer*, **1996**, 73, 154-61	8.7	80
62	Mechanisms of Resistance to Antiestrogens and Their Implications for Crossresistance **1996**, 93-122		
61	Estrogens, phytoestrogens, and breast cancer. *Advances in Experimental Medicine and Biology*, **1996**, 401, 63-85	3.6	17
60	Acquisition of an antiestrogen-resistant phenotype in breast cancer: role of cellular and molecular mechanisms. *Cancer Treatment and Research*, **1996**, 87, 263-83	3.5	13
59	Hormone dependence of breast cancer cells and the effects of tamoxifen and estrogen: 31P NMR studies. *Breast Cancer Research and Treatment*, **1995**, 33, 209-17	4.4	13
58	Acquisition of estrogen independence and antiestrogen resistance in breast cancer: association with the invasive and metastatic phenotype. *Endocrine-Related Cancer*, **1995**, 2, 27-35	5.7	
57	Cross-resistance and molecular mechanisms in antiestrogen resistance. *Endocrine-Related Cancer*, **1995**, 2, 59-72	5.7	13
56	Early life affects the risk of developing breast cancer. *Annals of the New York Academy of Sciences*, **1995**, 768, 327-30	6.5	8
55	Psychosocial factors in the development and progression of breast cancer. *Breast Cancer Research and Treatment*, **1994**, 29, 141-60	4.4	75
54	Hormonal carcinogenesis in breast cancer: cellular and molecular studies of malignant progression. *Breast Cancer Research and Treatment*, **1994**, 31, 237-48	4.4	52
53	Perinatal factors increase breast cancer risk. *Breast Cancer Research and Treatment*, **1994**, 31, 273-84	4.4	34
52	Anti-proliferative and anti-estrogenic effects of ICI 164,384 and ICI 182,780 in 4-OH-tamoxifen-resistant human breast-cancer cells. *International Journal of Cancer*, **1994**, 56, 295-300	7.5	61

#	Reference	IF	Cites
51	Effect of tamoxifen on the multidrug-resistant phenotype in human breast cancer cells: isobologram, drug accumulation, and M(r) 170,000 glycoprotein (gp170) binding studies. *Cancer Research*, **1994**, 54, 441-7	10.1	50
50	Resistance to TNF-alpha and adriamycin in the human breast cancer MCF-7 cell line: relationship to MDR1, MnSOD, and TNF gene expression. *Cancer Research*, **1994**, 54, 825-31	10.1	60
49	The invasive and metastatic properties of hormone-independent but hormone-responsive variants of MCF-7 human breast cancer cells. *Clinical and Experimental Metastasis*, **1993**, 11, 15-26	4.7	59
48	Opposing behavioural alterations in male and female transgenic TGF alpha mice: association with tumour susceptibility. *British Journal of Cancer*, **1993**, 67, 1026-30	8.7	14
47	Hormone resistance, invasiveness, and metastatic potential in breast cancer. *Breast Cancer Research and Treatment*, **1993**, 24, 227-39	4.4	54
46	MCF7/LCC2: a 4-hydroxytamoxifen resistant human breast cancer variant that retains sensitivity to the steroidal antiestrogen ICI 182,780. *Cancer Research*, **1993**, 53, 3229-32	10.1	140
45	Acquisition of hormone-independent growth in MCF-7 cells is accompanied by increased expression of estrogen-regulated genes but without detectable DNA amplifications. *Cancer Research*, **1993**, 53, 283-90	10.1	94
44	The biology of breast tumor progression. Acquisition of hormone independence and resistance to cytotoxic drugs. *Acta Oncologica*, **1992**, 31, 115-23	3.2	30
43	Effect of P-glycoprotein expression on sensitivity to hormones in MCF-7 human breast cancer cells. *Journal of the National Cancer Institute*, **1992**, 84, 1506-12	9.7	51
42	Alterations in behavior, steroid hormones and natural killer cell activity in male transgenic TGF alpha mice. *Brain Research*, **1992**, 588, 97-103	3.7	37
41	In vitro antineoplastic activity of C7-substituted mitomycin C analogues MC-77 and MC-62 against human breast-cancer cell lines. *Cancer Chemotherapy and Pharmacology*, **1992**, 29, 290-6	3.5	10
40	Hormonal aspects of breast cancer. Growth factors, drugs and stromal interactions. *Critical Reviews in Oncology/Hematology*, **1992**, 12, 1-23	7	117
39	Inhibition of growth of MCF-7 MIII human breast carcinoma in nude mice by treatment with agonists or antagonists of LH-RH. *Breast Cancer Research and Treatment*, **1992**, 21, 35-45	4.4	27
38	IGF-I and IGF-II expression in human breast cancer xenografts: relationship to hormone independence. *Breast Cancer Research and Treatment*, **1992**, 22, 39-45	4.4	26
37	Association of increased basement membrane invasiveness with absence of estrogen receptor and expression of vimentin in human breast cancer cell lines. *Journal of Cellular Physiology*, **1992**, 150, 534-44	7	397
36	Analysis of tyrosine kinase mRNAs including four FGF receptor mRNAs expressed in MCF-7 breast-cancer cells. *International Journal of Cancer*, **1992**, 50, 598-603	7.5	43
35	Vascular Non-genomic Effects of Estrogen **1992**, 145-159		4
34	The multidrug resistance phenotype: 31P nuclear magnetic resonance characterization and 2-deoxyglucose toxicity. *Cancer Research*, **1991**, 51, 1638-44	10.1	42

33 The process of malignant progression in human breast cancer. *Annals of Oncology*, **1990**, 1, 401-7 — 10.3 — 49

32 Reduction of the membrane fluidity of human breast cancer cells by tamoxifen and 17 beta-estradiol. *Journal of the National Cancer Institute*, **1990**, 82, 1702-5 — 9.7 — 98

31 Mechanisms of hormone and cytotoxic drug interactions in the development and treatment of breast cancer. *Progress in Clinical and Biological Research*, **1990**, 322, 243-78 — 1

30 Adverse interactions between cytotoxic drugs and hormonal agents in human breast cancer cells. *Journal of Clinical Oncology*, **1989**, 7, 1580-2 — 2.2 — 2

29 The inter-relationships between ovarian-independent growth, tumorigenicity, invasiveness and antioestrogen resistance in the malignant progression of human breast cancer. *Journal of Endocrinology*, **1989**, 122, 331-40 — 4.7 — 51

28 Regulation of breast cancer cells by hormones and growth factors: effects on proliferation and basement membrane invasiveness. *Hormone Research*, **1989**, 32 Suppl 1, 242-9 — 11

27 The effects of a constitutive expression of transforming growth factor-alpha on the growth of MCF-7 human breast cancer cells in vitro and in vivo. *Molecular Endocrinology*, **1989**, 3, 372-80 — 107

26 Progression of human breast cancer cells from hormone-dependent to hormone-independent growth both in vitro and in vivo. *Proceedings of the National Academy of Sciences of the United States of America*, **1989**, 86, 3649-53 — 11.5 — 141

25 Regulation of human breast cancer by secreted growth factors. *Acta Oncologica*, **1989**, 28, 835-9 — 3.2 — 22

24 Endocrine therapy of human breast cancer cells: the role of secreted polypeptide growth factors. *Cancer Cells*, **1989**, 1, 81-6 — 13

23 Conformational and receptor binding properties of human EGF and TGF-alpha second loop fragments. *Journal of Molecular Recognition*, **1988**, 1, 116-23 — 2.6 — 9

22 The ability of oestrogen to modulate the effects of cytotoxic drugs in human breast cancer cells: influence of oestrogen receptor status and choice of drug. *Biochemical Society Transactions*, **1987**, 15, 242-243 — 5.1

21 Morpho-functional effects of Phenol Red on oestrogen-sensitive breast cancer cells. *Biochemical Society Transactions*, **1987**, 15, 244-244 — 5.1 — 7

20 The response of human breast cancer cells to glucagon. *Biochemical Society Transactions*, **1987**, 15, 241-242 — 5.1 — 1

19 Pharmacological and suprapharmacological concentrations of both 17-bestradiol and tamoxifen reduce the membrane fluidity of MCF-7 and MDA-MB-436 human breast cancer cells. *Biochemical Society Transactions*, **1987**, 15, 243-244 — 5.1 — 11

18 Recombinant human interferon alpha increases oestrogen receptor expression in human breast cancer cells (ZR-75-1) and sensitizes them to the anti-proliferative effects of tamoxifen. *British Journal of Cancer*, **1987**, 55, 255-7 — 8.7 — 74

17 The effects of Mg2+ or EDTA on the subcellular distribution of unoccupied oestrogen receptor in ZR-75-1 and MCF-7 cells. *Biochemical Society Transactions*, **1986**, 14, 447-447 — 5.1

16 The influence of vincristine on the oestrogen-binding capacity of two human breast cancer cell lines in vitro. *Biochemical Society Transactions*, **1986**, 14, 449-450 — 5.1 — 1

15	The unoccupied estrogen receptor: some comments on localization. *Steroids*, **1986**, 48, 121-4	2.8	7
14	Enhancement of methotrexate cytotoxicity towards the MDA.MB.436 human breast cancer cell line by dipyridamole. The role of methotrexate polyglutamates. *Biochemical Pharmacology*, **1986**, 35, 3053-6	6	19
13	The effects of Mg2+ ions or EDTA on nuclear integrity and apparent subcellular distribution of unoccupied oestrogen receptors in breast cancer cells. *The Journal of Steroid Biochemistry*, **1986**, 25, 619-26		7
12	Effect of cytotoxic drugs on estrogen receptor expression and response to tamoxifen in MCF-7 cells. *Cancer Research*, **1986**, 46, 6116-9	10.1	18
11	Oestrogen receptor status and the response of human breast cancer cell lines to a combination of methotrexate and 17-beta oestradiol. *British Journal of Cancer*, **1985**, 51, 365-9	8.7	17
10	The effect of leucovorin on the synthesis of methotrexate poly-gamma-glutamates in the MCF-7 human breast cancer cell line. *Biochemical Pharmacology*, **1985**, 34, 2897-903	6	16
9	The effect of the rate of cell proliferation on the synthesis of methotrexate poly-gamma-glutamates in two human breast cancer cell lines. *Biochemical Pharmacology*, **1985**, 34, 3087-90	6	10
8	Reduction of the anti-metabolic and anti-proliferative effects of methotrexate by 17 beta-oestradiol in a human breast carcinoma cell line, MDA-MB-436. *European Journal of Cancer & Clinical Oncology*, **1983**, 19, 19-24		9
7	The kinetics of methotrexate polyglutamate formation and efflux in a human breast cancer cell line (MDA.MB.436): the effect of insulin. *Biochemical Pharmacology*, **1983**, 32, 41-6	6	24
6	Failure of 5-fluorouracil and methotrexate to destroy the reproductive integrity of a human breast cancer cell line (MCF-7) growing in vitro. *European Journal of Cancer & Clinical Oncology*, **1981**, 17, 1275-81		6
5	Normalization of microarray data by iterative nonlinear regression		1
4	Data-driven detection of subtype-specific and differentially expressed genes		1
3	Integrated Identification of Disease Specific Pathways Using Multi-omics data		1
2	SLCs contribute to endocrine resistance in breast cancer: role of SLC7A5 (LAT1)		4
1	swCAM: estimation of subtype-specific expressions in individual samples with unsupervised sample-wise deconvolution		1